{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T05:00:18Z","timestamp":1777698018954,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.ejmech.2019.05.089","type":"journal-article","created":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T02:02:01Z","timestamp":1559527321000},"page":"116-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy"],"prefix":"10.1016","volume":"178","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8915-9944","authenticated-orcid":false,"given":"Zhuang","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingsheng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minghai","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zihao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heying","family":"Pei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengshi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8076-163X","authenticated-orcid":false,"given":"Lijuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2019.05.089_bib1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.gene.2005.09.010","article-title":"Acetylation and deacetylation of non-histone proteins","volume":"363","author":"Glozak","year":"2005","journal-title":"Gene"},{"key":"10.1016\/j.ejmech.2019.05.089_bib2","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2019.05.089_bib3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J.\u00a0Clin. Investig."},{"key":"10.1016\/j.ejmech.2019.05.089_bib4","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/icb.2011.100","article-title":"HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications","volume":"90","author":"Khan","year":"2012","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.ejmech.2019.05.089_bib5","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ejmech.2016.05.047","article-title":"Inside HDACs with more selective HDAC inhibitors","volume":"121","author":"Roche","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.05.089_bib6","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2217\/epi.10.7","article-title":"Small-molecule chromatin-modifying agents: therapeutic applications","volume":"2","author":"Mai","year":"2010","journal-title":"Epigenomics"},{"key":"10.1016\/j.ejmech.2019.05.089_bib7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/ars.2013.5776","article-title":"Targeting histone deacetylases in diseases: where are we?","volume":"23","author":"Benedetti","year":"2015","journal-title":"Antioxidants Redox Signal."},{"key":"10.1016\/j.ejmech.2019.05.089_bib8","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1021\/acs.jproteome.7b00380","article-title":"Ultradeep lysine crotonylome reveals the crotonylation enhancement on both histones and nonhistone proteins by SAHA treatment","volume":"16","author":"Wu","year":"2017","journal-title":"J.\u00a0Proteome Res."},{"key":"10.1016\/j.ejmech.2019.05.089_bib9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nbt1272","article-title":"Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug","volume":"25","author":"Marks","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejmech.2019.05.089_bib10","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncol."},{"key":"10.1016\/j.ejmech.2019.05.089_bib11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1188\/12.CJON.195-204","article-title":"Romidepsin: a new drug for the treatment of cutaneous T-cell lymphoma","volume":"16","author":"Frye","year":"2012","journal-title":"Clin. J. Oncol. Nurs."},{"key":"10.1016\/j.ejmech.2019.05.089_bib12","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1158\/1078-0432.CCR-14-3119","article-title":"FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma","volume":"21","author":"Lee","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2019.05.089_bib13","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1158\/1078-0432.CCR-15-0530","article-title":"Panobinostat for the treatment of multiple myeloma","volume":"21","author":"Laubach","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2019.05.089_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.3807","article-title":"Review of bioanalytical assays for the quantitation of various HDAC inhibitors such as vorinostat, belinostat, panobinostat, romidepsin and chidamine","volume":"31","author":"Suresh","year":"2017","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.ejmech.2019.05.089_bib15","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/j.ejmech.2010.02.030","article-title":"Inside HDAC with HDAC inhibitors","volume":"45","author":"Bertrand","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.05.089_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejmech.2017.03.064","article-title":"Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors","volume":"133","author":"Chen","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.05.089_bib17","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ejmech.2018.08.073","article-title":"HDAC as onco target: reviewing the synthetic approaches with SAR study of their inhibitors","volume":"158","author":"Sangwan","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.05.089_bib18","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.molonc.2012.09.003","article-title":"HDAC inhibitor-based therapies: can we interpret the code?","volume":"6","author":"New","year":"2012","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ejmech.2019.05.089_bib19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2008.08.016","article-title":"HDAC family: what are the cancer relevant targets?","volume":"277","author":"Witt","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2019.05.089_bib20","doi-asserted-by":"crossref","first-page":"6297","DOI":"10.1021\/jm4001659","article-title":"Development and therapeutic implications of selective histone deacetylase 6 inhibitors","volume":"56","author":"Kalin","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.05.089_bib21","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.drudis.2015.01.007","article-title":"Histone deacetylases: structural determinants of inhibitor selectivity","volume":"20","author":"Micelli","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2019.05.089_bib22","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.2174\/0929867311320140005","article-title":"Histone deacetylase inhibitors: an attractive strategy for cancer therapy","volume":"20","author":"Li","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.05.089_bib23","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ejmech.2018.08.073","article-title":"HDAC as onco target: reviewing the synthetic approaches with SAR study of their inhibitors","volume":"158","author":"Sangwan","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.05.089_bib24","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1021\/acs.jmedchem.8b01090","article-title":"Synthesis and biological investigation of phenothiazine-based benzhydroxamic acids as selective histone deacetylase 6 inhibitors","volume":"62","author":"Vogerl","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.05.089_bib25","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1021\/acs.jmedchem.8b01590","article-title":"Quinazolin-2,4-dione-Based hydroxamic acids as selective histone deacetylase-6 inhibitors for treatment of non-small-cell lung cancer","volume":"62","author":"Yu","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.05.089_bib26","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1021\/acs.jmedchem.8b00189","article-title":"Kinase and histone deacetylase hybrid inhibitors for cancer therapy","volume":"62","author":"Luan","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.05.089_bib27","doi-asserted-by":"crossref","first-page":"7087","DOI":"10.1021\/acs.jmedchem.8b00151","article-title":"5-Aroylindoles act as selective histone deacetylase 6 inhibitors ameliorating alzheimer's disease phenotypes","volume":"61","author":"Lee","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.05.089_bib28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejmech.2017.03.064","article-title":"Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors","volume":"133","author":"Chen","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.05.089_bib29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejmech.2017.03.079","article-title":"4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in\u00a0vitro and in\u00a0vivo","volume":"134","author":"Mehndiratta","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.05.089_bib30","article-title":"Discovery of a novel dual histone deacetylases (HDACs) and mammalian target of rapamycin (mTOR) target inhibitor as a promising strategy for cancer therapy","author":"Chen","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.05.089_bib31","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1021\/acs.jmedchem.5b01342","article-title":"Discovery of selective histone deacetylase 6 inhibitors using the quinazoline as the cap for the treatment of cancer","volume":"59","author":"Yang","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.05.089_bib32","doi-asserted-by":"crossref","first-page":"5488","DOI":"10.1021\/acs.jmedchem.6b00579","article-title":"Development of purine-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in\u00a0vitro and in\u00a0vivo antitumor activities","volume":"59","author":"Chen","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.05.089_bib33","doi-asserted-by":"crossref","first-page":"6259","DOI":"10.1021\/jm500303u","article-title":"1,3,4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells","volume":"57","author":"Valente","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.05.089_bib34","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nchembio.2140","article-title":"Structural insights into HDAC6 tubulin deacetylation and its selective inhibition","volume":"12","author":"Miyake","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2019.05.089_bib35","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nchembio.2134","article-title":"Histone deacetylase 6 structure and molecular basis of catalysis and inhibition","volume":"12","author":"Hai","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2019.05.089_bib36","doi-asserted-by":"crossref","first-page":"11262","DOI":"10.1038\/ncomms11262","article-title":"Insights into the activation mechanism of class I HDAC complexes by inositol phosphates","volume":"7","author":"Watson","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2019.05.089_bib37","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1021\/ci400550m","article-title":"Docking ligands into flexible and solvated macromolecules. 6. Development and application to the docking of HDACs and other zinc metalloenzymes inhibitors","volume":"54","author":"Pottel","year":"2014","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2019.05.089_bib38","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.2174\/0929867324666170209105315","article-title":"Progress in the discovery of macrocyclic histone deacetylase inhibitors for the treatment of cancer","volume":"24","author":"Cheng","year":"2017","journal-title":"Curr. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419305136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419305136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:55:03Z","timestamp":1759326903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523419305136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":38,"alternative-id":["S0223523419305136"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.05.089","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.05.089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}